Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy

被引:2
|
作者
Higashiyama, Tomoaki [1 ]
Ohji, Masahito [1 ]
机构
[1] Shiga Univ Med Sci, Dept Ophthalmol, Tsukinowa Cho, Otsu, Shiga 5202192, Japan
来源
CLINICAL OPHTHALMOLOGY | 2018年 / 12卷
关键词
bimatoprost; thyroid-associated ophthalmopathy; exophthalmos; orbital fat;
D O I
10.2147/OPTH.S187164
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost. Methods: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion. Results: Nine orbits of nine patients (eight women, one man) were treated with bimatoprost for 12 months. Mean exophthalmos values before and after treatment were 21.7 +/- 2.2 and 21.7 +/- 2.0 mm, respectively. The mean value after 12 months of treatment was not significantly different from before treatment (P=0.82). Mean orbital fat volume before and after 12 months of treatment was 17.2 +/- 2.5 and 17.0 +/- 3.0 cm(3), respectively. The corresponding total extraocular muscle volume was 4.0 +/- 0.7 and 3.8 +/- 0.9 cm(3), respectively. Mean volume in each tissue type after 12 months of treatment was not significantly different from before treatment (orbital fat, P=0.70; extraocular muscles, P=0.32). Conclusion: Topical bimatoprost treatment did not reduce exophthalmos or orbital fat in this cohort of patients with inactive TAO.
引用
收藏
页码:2415 / 2421
页数:7
相关论文
共 50 条
  • [31] Reduced cortical complexity in patients with thyroid-associated ophthalmopathy
    Zhou, Jiang
    Chen, Wen
    Wu, Qian
    Chen, Lu
    Chen, Huan-Huan
    Liu, Hu
    Xu, Xiao-Quan
    Wu, Fei-Yun
    Hu, Hao
    BRAIN IMAGING AND BEHAVIOR, 2022, 16 (05) : 2133 - 2140
  • [32] Ocular pulse amplitude in patients with thyroid-associated ophthalmopathy
    Bozic, Marija M.
    Knezevic, Miroslav M.
    Risimic, Dijana S.
    Cubrilo, Katarina M.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2013, 23 (03) : 284 - 288
  • [33] A retrospective study of elderly patients with thyroid-associated ophthalmopathy
    Sun, Bin
    Zhang, Zhaoxia
    Jing, Liping
    Yan, Chunfang
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [34] Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy
    Khanna, Dinesh
    Chong, Kelvin K. L.
    Afifiyan, Nikoo F.
    Hwang, Catherine J.
    Lee, Diana K.
    Garneau, Helene Chokron
    Goldberg, Robert A.
    Darwin, Christine H.
    Smith, Terry J.
    Douglas, Raymond S.
    OPHTHALMOLOGY, 2010, 117 (01) : 133 - U167
  • [35] RECOGNIZING AND TREATING THYROID-ASSOCIATED OPHTHALMOPATHY
    COLE, M
    MITCHELL, S
    PAISEY, R
    YELDHAM, D
    PRACTITIONER, 1995, 239 (1549) : 261 - 263
  • [36] 2021 update on thyroid-associated ophthalmopathy
    E. J. Neag
    T. J. Smith
    Journal of Endocrinological Investigation, 2022, 45 : 235 - 259
  • [37] Thyroid-associated ophthalmopathy: a new sign
    Gallenga, PE
    Mastropasqua, L
    Mancini, A
    Ciancaglini, M
    Zuppardi, E
    Lobefalo, L
    ULTRASONOGRAPHY IN OPHTHALMOLOGY XV, 1997, 61 : 371 - 376
  • [38] Ophthalmological evaluation in thyroid-associated ophthalmopathy
    Åsman, P
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2003, 81 (05): : 437 - 448
  • [39] Animal models of thyroid-associated ophthalmopathy
    Ludgate, ME
    THYROID, 2002, 12 (03) : 205 - 208
  • [40] 2021 update on thyroid-associated ophthalmopathy
    Neag, E. J.
    Smith, T. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 235 - 259